Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)

Inclusion Criteria: * Male and female CKD subjects with or without dialysis treatment * Age \> 18 years * Subjects under documented stable maintenance therapy with ESA, s.c. at least once per week and in accordance with the relevant SmPC, for at least 3 months with a total weekly dose of ≤ 300 IU/kg/week * Subjects with controlled symptomatic anemia, defined as mean Hb level between 10.0 g/dL and 12.0 g/dL, based on four Hb measurements during the four-week baseline period * Adequate iron status, serum ferritin ≥ 100 µg/L or transferrin saturation ≥ 20% * Confirmed negative anti-EPO antibody assay from sample taken at screening visit -4 Exclusion Criteria: * Systemic cyclosporine * History of PRCA or aplastic anemia * History of anti-EPO antibodies * Uncontrolled hypertension